electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to non-invasive nerve stimulation with mobile devices.

U.S. Patent No. 11,766,562 entitled “Nerve Stimulator for Use with a Mobile Device” was issued on September 26, 2023, and is generally related to treating seizures, such as epileptic seizures that utilizes a system for transcutaneously stimulating a nerve within a patient whereby the system includes the stimulator and a mobile device that provides a wireless signal to enable the stimulator to operate.

“We continue to broaden our intellectual property portfolio and strengthen our position around systems utilizing mobile devices to control stimulators,” stated Dan Goldberger, Chief Executive Officer of electroCore. “The addition of this new patent is an example of how electroCore’s nVNS technology may be expanded in the future to cover neurological and psychiatric conditions, and how our robust patent portfolio covering the use of mobile devices to operate a nerve stimulator may be leveraged in our new suite of products and devices.”

About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.

For more information, visit www.electrocore.com.

Forward-Looking StatementsThis press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and clinical and product development plans including potential commercial applications of nVNS via mobile devices in treating seizures or certain neurological or psychiatric conditions; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the issuance of U.S. and international patents, including patents related to non-invasive nerve stimulation with mobile devices, providing expanded IP coverage; the possibility of future business models, the potential of nVNS generally and gammaCore in particular and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to obtain additional financing necessary to continue electroCore's business, sales and marketing and product development plans, the uncertainties inherent in the development of new products or technologies, the ability to successfully commercialize gammaCore™, competition in the industry in which electroCore operates and general market conditions. All forward-looking statements are made as of the date of this press release, and electroCore undertakes no obligation to update forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should refer to all information set forth in this document and should also refer to the disclosure of risk factors set forth in the reports and other documents electroCore files with the SEC, available at www.sec.gov.Contact:ECOR Investor Relations(973) [e-mail]